Latest Cancer News

Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer (06-26-2017)

Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to the results of a major study released at the American Society of Clinical Oncology’s annual meeting. The goal of the study was to determine [...]


FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation (06-26-2017)

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of patients with BRAF [...]


Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer (06-22-2017)

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to [...]


Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (06-20-2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; [...]


FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma (06-19-2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy.  CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being [...]


With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma (06-15-2017)

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used [...]


Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (06-14-2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients with the condition and, in many ways, ushered in the era [...]


Alecensa Superior to Xalkori in Treatment of Lung Cancer (06-12-2017)

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small [...]


FDA Expands use of Zykadia® in First-Line ALK-Positive Non-Small Cell Lung Cancer (06-9-2017)

The US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose cancers are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. About Zykadia Zykadia is an oral, selective inhibitor of ALK, [...]


Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer (06-9-2017)

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly [...]


Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (06-7-2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months to 33 months according to the results of a clinical study [...]


Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer (06-6-2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer patients have a B-raf mutation that can be specifically targeted [...]


Next Page »